The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index; none of the 92 sources its claims cite is checked for support yet.
CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought
Open accessAbstract
CDK4/6 inhibitors are among a new generation of therapeutics. Building upon the striking success of the combination of CDK4/6 inhibitors and the hormone receptor antagonist letrozole in breast cancer, many other combinations have recently entered clinical trials in multiple diseases. To achieve maximal benefit with CDK4/6 inhibitors it will be critical to understand the cellular mechanisms by which they act. Here we highlight the mechanisms by which CDK4/6 inhibitors can exert their anti-tumor activities beyond simply enforcing cytostatic growth arrest, and discuss how this knowledge may inform new combinations, improve outcomes, and modify dosing schedules in the future.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 of 92 cited sources checked · 0 supported · 0 flagged
None of the sources cited for this claim have been checked yet.
In the paper
“In vitro studies using cyclin D1/CDK4 and various cyclin D/CDK6 kinases determined that both abemaciclib and ribociclib are more potent against CDK4 than CDK6 (Gelbert et al., 2014; Tripathy et al., 2017) (Table 1).”
§ CDK4/6 inhibitors: The mechanism of action may not be as simple as once thought > CDK4/6 INHIBITORS: A TRIO OF COMPOUNDS WITH DISTINCT ADVANTAGES
What the sources say
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Here we highlight the mechanisms by which CDK4/6 inhibitors can exert their anti-tumor activities beyond simply enforcing cytostatic growth arrest”
§ CDK4/6 inhibitors: The mechanism of action may not be as simple as once thought > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes? Based: unclear- Rests on an assumption: The mechanisms of CDK4/6 inhibitor action observed in preclinical models are relevant to their clinical effects in human cancers.
In the paper
“Such pan-CDK inhibitors had limited success, due in part to the dose limiting toxicities that hampered their use (Asghar et al., 2015).”
§ CDK4/6 inhibitors: The mechanism of action may not be as simple as once thought > THE IMPORTANCE OF CYCLIN D-CDK4/6 IN THE CELL CYCLE
What the sources say
- Not checked yetcites Asghar et al., 2015 source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIn the paper
“CDK4/6 activity bridges numerous extracellular signaling pathways to the cell cycle (Sherr and Roberts, 1999).”
§ CDK4/6 inhibitors: The mechanism of action may not be as simple as once thought > THE IMPORTANCE OF CYCLIN D-CDK4/6 IN THE CELL CYCLE
What the sources say
- Not checked yetcites Sherr and Roberts, 1999 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIn the paper
“Although palbociclib was the first CDK4/6 inhibitor to demonstrate clinical efficacy (Finn et al., 2016), there are two others that soon followed.”
§ CDK4/6 inhibitors: The mechanism of action may not be as simple as once thought > CDK4/6 INHIBITORS: A TRIO OF COMPOUNDS WITH DISTINCT ADVANTAGES
What the sources say
- Not checked yetcites Finn et al., 2016 source
Strength:boosted· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesNone of the sources cited for this claim have been checked yet.
In the paper
“This may translate to higher cerebrospinal fluid concentrations for ribocliclib compared to palbociclib and abemaciclib as noted in mouse models (DiPippo et al., 2016; Raub et al., 2015; Yin et al., 2017).”
§ CDK4/6 inhibitors: The mechanism of action may not be as simple as once thought > CDK4/6 INHIBITORS: A TRIO OF COMPOUNDS WITH DISTINCT ADVANTAGES
What the sources say
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesNone of the sources cited for this claim have been checked yet.
In the paper
“The growth suppressive properties of Rb are largely, but not completely, associated with its binding to the transcription factor E2F and repressing transcription at target promoters (Classon and Harlow, 2002; Harbour and Dean, 2000; Stevaux and Dyson, 2002).”
§ CDK4/6 inhibitors: The mechanism of action may not be as simple as once thought > THE IMPORTANCE OF CYCLIN D-CDK4/6 IN THE CELL CYCLE
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIn the paper
“In such assays, abemaciclib also has modest activity, relative to its CDK4 inhibitory activity, against cyclin T1/CDK9, cyclin E2/CDK2, p25/CDK5 and p35/CDK5 (Gelbert et al., 2014) (Table 2).”
§ CDK4/6 inhibitors: The mechanism of action may not be as simple as once thought > CDK4/6 INHIBITORS: A TRIO OF COMPOUNDS WITH DISTINCT ADVANTAGES
What the sources say
- Not checked yetcites Gelbert et al., 2014 source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesNone of the sources cited for this claim have been checked yet.
In the paper
“CDK4/6 kinases can phosphorylate factors involved in cell differentiation affecting their transcriptional activity, apoptotic factors affecting their activity, and other factors that can directly affect mitochondrial activity (Hydbring et al., 2016; Lim and Kaldis, 2013).”
§ CDK4/6 inhibitors: The mechanism of action may not be as simple as once thought > THE IMPORTANCE OF CYCLIN D-CDK4/6 IN THE CELL CYCLE
What the sources say
- Not checked yetcites Hydbring et al., 2016 source
- Not checked yetcites Lim and Kaldis, 2013
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIn the paper
“In virtually all human cancer cells, this circuit is dysregulated by either overexpression of cyclin D1, loss of p16Ink4a, the mutation of CDK4 to an Ink4-refractory state, or the loss of Rb itself (Classon and Harlow, 2002).”
§ CDK4/6 inhibitors: The mechanism of action may not be as simple as once thought > THE IMPORTANCE OF CYCLIN D-CDK4/6 IN THE CELL CYCLE
What the sources say
- Not checked yetcites Classon and Harlow, 2002 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes
- It may state two separate claims as one. 28
- Probably not a substantial claim. 5
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Ribociclib is notable for achieving high maximum plasma concentrations (exceeding 2 µg/ml) with a long half-life (greater than 30 hours).”
§ CDK4/6 inhibitors: The mechanism of action may not be as simple as once thought > CDK4/6 INHIBITORS: A TRIO OF COMPOUNDS WITH DISTINCT ADVANTAGES
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“All three CDK4/6 inhibitors are orally available, but each has differing pharmacokinetics and clinical toxicities (Table 1), necessitating different dosing strategies.”
§ CDK4/6 inhibitors: The mechanism of action may not be as simple as once thought > CDK4/6 INHIBITORS: A TRIO OF COMPOUNDS WITH DISTINCT ADVANTAGES
What the sources say
- Not checked yetcites Table 1
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Both non-immortal non-transformed cells (hereafter referred to as ‘normal’ cells) and many transformed tumor cells commit irreversibly to the mitotic cell cycle in the G1 phase. Commitment depends on the phosphorylation and inactivation of the retinoblastoma tumor suppressor protein, Rb.”
§ CDK4/6 inhibitors: The mechanism of action may not be as simple as once thought > THE IMPORTANCE OF CYCLIN D-CDK4/6 IN THE CELL CYCLE
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Indeed, quiescent CDK4/6 inhibitor arrested liposarcoma tumor cells are pushed into senescence upon knocking down HRAS, and enforced expression of near physiologic levels of HRAS mRNA is able to prevent cells from undergoing senescence following treatment with CDK4/6 inhibitors albeit they still exit the cell cycle (Kovatcheva 2017).”
§ CDK4/6 inhibitors: The mechanism of action may not be as simple as once thought > SENESCENCE AFTER CDK4/6 INHIBITOR INDUCED GROWTH ARREST
What the sources say
- Not checked yetcites Kovatcheva 2017 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This outcome may be an important consideration when deciding whether to treat with abemaciclib or palbociclib/ribociclib, given their differing dosing schedules.”
§ CDK4/6 inhibitors: The mechanism of action may not be as simple as once thought > SENESCENCE AFTER CDK4/6 INHIBITOR INDUCED GROWTH ARREST
Tests✓ Asserted: passes✗ Checkable: fails✓ Load-bearing: passes✗ Based: failsProbably not a substantial claim. It may be too vague to check against evidence. The paper may give no reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Abemaciclib appears to be better tolerated overall, with only 55% of patients experiencing significant adverse events (as compared to 70–80% with ribociclib and palbociclib) and only 21% with grade 3–4 neutropenia.”
§ CDK4/6 inhibitors: The mechanism of action may not be as simple as once thought > CDK4/6 INHIBITORS: A TRIO OF COMPOUNDS WITH DISTINCT ADVANTAGES
What the sources say
Strength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“On one hand, the SASP can induce the recruitment of immune cells that will mediate tumor clearance (Xue et al., 2007), or promote paracrine senescence (Acosta et al., 2013; Acosta et al., 2008).”
§ CDK4/6 inhibitors: The mechanism of action may not be as simple as once thought > SENESCENCE AFTER CDK4/6 INHIBITOR INDUCED GROWTH ARREST
What the sources say
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“However, 10% of the patients treated with abemaciclib develop grade 3 diarrhea, which is very rare with the other two inhibitors (Asghar et al., 2015; Hortobagyi et al., 2016).”
§ CDK4/6 inhibitors: The mechanism of action may not be as simple as once thought > CDK4/6 INHIBITORS: A TRIO OF COMPOUNDS WITH DISTINCT ADVANTAGES
What the sources say
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“It has also been suggested that the mammalian target of rapamycin (mTOR) can toggle the decision between quiescence and senescence (Korotchkina et al., 2010; Leontieva et al., 2012).”
§ CDK4/6 inhibitors: The mechanism of action may not be as simple as once thought > SENESCENCE AFTER CDK4/6 INHIBITOR INDUCED GROWTH ARREST
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Due to the significant myelotoxicity of palbociclib and ribociclib, both drugs require dose-interruption and are administered on a three-weeks-on / one-week-off schedule to allow marrow recovery.”
§ CDK4/6 inhibitors: The mechanism of action may not be as simple as once thought > CDK4/6 INHIBITORS: A TRIO OF COMPOUNDS WITH DISTINCT ADVANTAGES
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Nevertheless, knockdown of FOXM1 does not completely recapitulate the senescence effect of CDK4/6 inhibition, suggesting CDK4/6 inhibitors have functions in addition to suppression of FOXM1.”
§ CDK4/6 inhibitors: The mechanism of action may not be as simple as once thought > SENESCENCE AFTER CDK4/6 INHIBITOR INDUCED GROWTH ARREST
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“In contrast to this however, mTOR inhibition is crucial to reach oncogene induced senescence in mouse models of melanoma, and mTOR inhibition can cooperate with CDK4/6 inhibition to drive senescence in melanoma cell lines (Damsky et al., 2015; Yoshida et al., 2016).”
§ CDK4/6 inhibitors: The mechanism of action may not be as simple as once thought > SENESCENCE AFTER CDK4/6 INHIBITOR INDUCED GROWTH ARREST
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Unlike quiescent cells, senescent cells will not return to the cell cycle following removal of the inducing signal and are generally refractory to other proliferation-inducing signals (Rodier and Campisi, 2011).”
§ CDK4/6 inhibitors: The mechanism of action may not be as simple as once thought > SENESCENCE AFTER CDK4/6 INHIBITOR INDUCED GROWTH ARREST
What the sources say
- Not checked yetcites Rodier and Campisi, 2011 source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“CDK4/6 inhibition leads to the loss of multi-site phosphorylation and the destabilization of the transcription factor Forkhead Box M1 (FOXM1) (Anders et al., 2011).”
§ CDK4/6 inhibitors: The mechanism of action may not be as simple as once thought > SENESCENCE AFTER CDK4/6 INHIBITOR INDUCED GROWTH ARREST
What the sources say
- Not checked yetcites Anders et al., 2011 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“CDK4/6 inhibition can also alter cellular metabolism, depleting antioxidants, increasing reactive oxygen species (ROS) and triggering apoptosis.”
§ CDK4/6 inhibitors: The mechanism of action may not be as simple as once thought > CDK4/6 INHIBITORS REINFORCE CYTOSTASIS INDUCED BY SIGNALING PATHWAY INHIBITORS
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes? Based: unclearIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In summary, all three inhibitors target the proliferative function of the cyclin D associated kinases in Rb positive tumor cells to induce cell cycle exit and they are largely inactive in Rb negative cells.”
§ CDK4/6 inhibitors: The mechanism of action may not be as simple as once thought > CDK4/6 INHIBITORS: A TRIO OF COMPOUNDS WITH DISTINCT ADVANTAGES
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Other rodent models indicate a strong efflux of palbociclib out of the central nervous system, and less so for abemaciclib (Raub et al., 2015).”
§ CDK4/6 inhibitors: The mechanism of action may not be as simple as once thought > CDK4/6 INHIBITORS: A TRIO OF COMPOUNDS WITH DISTINCT ADVANTAGES
What the sources say
- Not checked yetcites Raub et al., 2015 source
Strength:hedged· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“CDK4/6 inhibition can also affect both the maturation of sentinel cells of the immune system and the expansion of regulatory T-cells.”
§ CDK4/6 inhibitors: The mechanism of action may not be as simple as once thought > CDK4/6 INHIBITORS REINFORCE CYTOSTASIS INDUCED BY SIGNALING PATHWAY INHIBITORS
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes? Based: unclearIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“These cells express very low levels of cyclin D1, cyclin D2, and CDK4, and the proliferative decision is dependent upon cyclin D3 and CDK6 (Wang et al., 2017; Wolowiec et al., 1996).”
§ CDK4/6 inhibitors: The mechanism of action may not be as simple as once thought > THE IMPACT OF CDK4/6 INHIBITORS ON CELLULAR METABOLISM
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“In contrast, CDK4 phosphorylation of GCN5 can lead to acetylation of PGC-1α and is associated with decreased glucose metabolism in hepatic cells (Lee et al., 2014).”
§ CDK4/6 inhibitors: The mechanism of action may not be as simple as once thought > THE IMPACT OF CDK4/6 INHIBITORS ON CELLULAR METABOLISM
What the sources say
- Not checked yetcites Lee et al., 2014 source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Combining CDK4/6 inhibition with an mTOR inhibitor, a BCL2 inhibitor, or reducing the ROS scavengers drives these cells into apoptosis, whereas treatment with single agents alone is not sufficient.”
§ CDK4/6 inhibitors: The mechanism of action may not be as simple as once thought > THE IMPACT OF CDK4/6 INHIBITORS ON CELLULAR METABOLISM
What the sources say
- Not checked yetcites Franco et al., 2016 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus, CDK4 is required for both the proliferation of tumor cells and for the maturation of the tumor microenvironment, and both are necessary for the progression of disease in this model.”
§ CDK4/6 inhibitors: The mechanism of action may not be as simple as once thought > CDK4/6 IN THE TUMOR MICROENVIRONMENT
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Indeed, persistent senescent cells may contribute to detrimental short and long-term side effects of treatment, as well as to metastases and relapse (Demaria et al., 2017).”
§ CDK4/6 inhibitors: The mechanism of action may not be as simple as once thought > SENESCENCE AFTER CDK4/6 INHIBITOR INDUCED GROWTH ARREST
What the sources say
- Not checked yetcites Demaria et al., 2017 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Consistent with this, the number of CD3+ cells recruited into the tumor mass increases after treatment, allowing for the stimulation of cytotoxic T-cells (CTLs).”
§ CDK4/6 inhibitors: The mechanism of action may not be as simple as once thought > CDK4/6 IN THE TUMOR MICROENVIRONMENT
What the sources say
- Not checked yetcites Goel et al., 2017 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“It is likely that the changes in metabolism after CDK4/6 inhibition will be context-specific and may be dependent on the oncogenic drivers that set up unique metabolic pathways and vulnerabilities.”
§ CDK4/6 inhibitors: The mechanism of action may not be as simple as once thought > THE IMPACT OF CDK4/6 INHIBITORS ON CELLULAR METABOLISM
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The extraordinarily complex microenvironment is not only supportive for growth but can also drive the transition of slow growing, indolent tumors into a more aggressive state.”
§ CDK4/6 inhibitors: The mechanism of action may not be as simple as once thought > CDK4/6 IN THE TUMOR MICROENVIRONMENT
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
In the paper
“This has the effect of pushing glycolytic intermediates into the pentose phosphate and serine pathways, and inhibition of CDK6 (through treatment with palbociclib, ribociclib, or knockdown of CDK6) depletes the antioxidants NADPH and glutathione, increasing ROS and apoptosis.”
§ CDK4/6 inhibitors: The mechanism of action may not be as simple as once thought > THE IMPACT OF CDK4/6 INHIBITORS ON CELLULAR METABOLISM
What the sources say
- Not checked yetcites Wang et al., 2017 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“CDK4/6 inhibition is also able to stimulate PD-1 expressing T-cells in vitro and enhance T cell infiltration (Deng et al., 2017).”
§ CDK4/6 inhibitors: The mechanism of action may not be as simple as once thought > CDK4/6 IN THE TUMOR MICROENVIRONMENT
What the sources say
- Not checked yetcites Deng et al., 2017 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“the combination of CDK4/6 and PI3K inhibitors increases the expression of HLA antigens leading to an increase in tumor-infiltrating cytotoxic CD4+ and CD8+ T cells and natural killer cells, and a decrease in the CD4+FOXP3+ Treg suppressor cells (Teo et al., 2017).”
§ CDK4/6 inhibitors: The mechanism of action may not be as simple as once thought > CDK4/6 IN THE TUMOR MICROENVIRONMENT
What the sources say
- Not checked yetcites Teo et al., 2017 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Treatment with palbociclib inhibits SPOP phosphorylation, promoting its degradation and blocking PD-L1 proteasome mediated degradation.”
§ CDK4/6 inhibitors: The mechanism of action may not be as simple as once thought > CDK4/6 IN THE TUMOR MICROENVIRONMENT
What the sources say
- Not checked yetcites Zhang et al., 2018 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Collectively, these observations suggest that the most effective approach to harness the senescence promoting effects of CDK4/6 inhibitors may be to first induce senescence and then eliminate the persistent senescent cells.”
§ CDK4/6 inhibitors: The mechanism of action may not be as simple as once thought > SENESCENCE AFTER CDK4/6 INHIBITOR INDUCED GROWTH ARREST
Tests✓ Asserted: passes✗ Checkable: fails✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may be too vague to check against evidence.
- Rests on an assumption: The senescence and SASP programs induced by CDK4/6 inhibitors in model systems are representative of those in human tumors.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Evidence that BCL2 inhibitors can directly eliminate senescent cells (Chang et al., 2016; Yosef et al., 2016) suggests that combining this with other cancer therapies in a sequential manner might be useful.”
§ CDK4/6 inhibitors: The mechanism of action may not be as simple as once thought > SENESCENCE AFTER CDK4/6 INHIBITOR INDUCED GROWTH ARREST
Tests✓ Asserted: passes✗ Checkable: fails✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may be too vague to check against evidence.
In the paper
“In the oligodendroglioma model described above (Ciznadija et al., 2011), ectopic PDGF expression is sufficient to drive the initiation of disease in CDK4 positive tumor cells, but if the microenvironment is CDK4 deficient these low-grade lesions would not progress to high grade lethal malignancies.”
§ CDK4/6 inhibitors: The mechanism of action may not be as simple as once thought > CDK4/6 IN THE TUMOR MICROENVIRONMENT
What the sources say
- Not checked yetcites Ciznadija et al., 2011 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper relies on this without support.
The mechanisms of CDK4/6 inhibitor action observed in preclinical models are relevant to their clinical effects in human cancers.
“Here we highlight the mechanisms by which CDK4/6 inhibitors can exert their anti-tumor activities beyond simply enforcing cytostatic growth arrest and discuss how this knowledge may inform new combinations, improve outcomes and modify dosing schedules in the future.”
The paper relies on this without support.
The senescence and SASP programs induced by CDK4/6 inhibitors in model systems are representative of those in human tumors.
“Collectively, these observations suggest that the most effective approach to harness the senescence promoting effects of CDK4/6 inhibitors may be to first induce senescence and then eliminate the persistent senescent cells.”
The paper relies on this without support.
Rb-negative tumors do not respond significantly to CDK4/6 inhibitors.
“Given the importance of CDK4 in the tumor microenvironment, it may be somewhat surprising that CDK4/6 inhibitors have no significant effect on Rb-negative tumors.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Accumulating evidence suggests that CDK4/CDK6 inhibitors, as well as inhibitors of other CDKs, do not only arrest the proliferation of malignant cells, they also mediate multipronged immunomodulatory effects (Klein et al., 2018; Petroni et al., 2020)”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Klein et al., 2018
Citations
Cites
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
The senescence-associated secretory phenotype: the dark side of tumor suppression
Coppé, J.-P., Desprez, P.-Y., Krtolica, A., & Campisi, J. (2010) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-121808-102144 · Cited by 5,206
Palbociclib and letrozole in advanced breast cancer
Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607303 · Cited by 3,007
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473
A complex secretory program orchestrated by the inflammasome controls paracrine senescence
Acosta, J. C., Banito, A., Wuestefeld, T., Georgilis, A., Janich, P., Morton, J. P., Athineos, D., Kang, T.-W., Lasitschka, F., Andrulis, M., et al. (2013) · Nature Cell Biology · doi:10.1038/ncb2784 · Cited by 2,278 · cited 1×
“, 2007), or promote paracrine senescence (Acosta et al., 2013; Acosta et al., 2008).”
Four faces of cellular senescence
Rodier, F., & Campisi, J. (2011) · Journal of Cell Biology · doi:10.1083/jcb.201009094 · Cited by 2,070 · cited 1×
“Unlike quiescent cells, senescent cells will not return to the cell cycle following removal of the inducing signal and are generally refractory to other proliferation-inducing signals (Rodier and Campisi, 2011).”
BackgroundRibociclib as first-line therapy for HR-positive, advanced breast cancer
Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Blackwell, K. L., André, F., Winer, E. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609709 · Cited by 2,039 · cited 2×
“However, 10% of the patients treated with abemaciclib develop grade 3 diarrhea, which is very rare with the other two inhibitors (Asghar et al., 2015; Hortobagyi et al., 2016).”
BackgroundClearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice
Chang, J., Wang, Y., Shao, L., Laberge, R.-M., Demaria, M., Campisi, J., Janakiraman, K., Sharpless, N. E., Ding, S., Feng, W., et al. (2016) · Nature Medicine · doi:10.1038/nm.4010 · Cited by 1,819
The history and future of targeting cyclin-dependent kinases in cancer therapy
Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4504 · Cited by 1,767
Krtolica, A., Parrinello, S., Lockett, S., Desprez, P.-Y., & Campisi, J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.211053698 · Cited by 1,730
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 383
Degradation strategy of cyclin D1 in cancer cells and the potential clinical application
Chen, S., & Li, L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.949688 · Cited by 37
CDK4/6 inhibitors in lung cancer: current practice and future directions
Lv, S., Yang, J., Lin, J., Huang, X., Zhao, H., Zhao, C., & Yang, L. (2024) · European Respiratory Review · doi:10.1183/16000617.0145-2023 · Cited by 35
Immunotherapy in pancreatic cancer: New hope or mission impossible?
Jiang, J., Zhou, H., Ni, C., Hu, X., Mou, Y., Huang, D., & Yang, L. (2019) · Cancer Letters · doi:10.1016/j.canlet.2018.10.045 · Cited by 37
Bao, X., Wu, J., Sanai, N., & Li, J. (2019) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2019.01.017 · Cited by 34
Tong, Z., Sathe, A., Ebner, B., Pan, Q., Veltkamp, C., Gschwend, J. E., Holm, P. S., & Nawroth, R. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1322-9 · Cited by 36
Gini, B., Thomas, N. J., & Blakely, C. M. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2020.03.78 · Cited by 38
Yousuf, M., Alam, M., Shamsi, A., Κhan, P., Hasan, G. M., Haque, Q. M. R., & Hassan, M. I. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.07.156 · Cited by 36
Heat shock proteins and cancer: The FoxM1 connection
Alimardan, Z., Abbasi, M., Hasanzadeh, F., Aghaei, M., Khodarahmi, G., & Kashfi, K. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115505 · Cited by 35
Immunomodulatory effects of CDK4/6 inhibitors
Zhang, S., Xu, Q., Sun, W., Zhou, J., & Zhou, J. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188912 · Cited by 34
Santiappillai, N. T., AbuHammad, S., Slater, A. A., Kirby, L., McArthur, G. A., Sheppard, K. E., & Smith, L. K. (2021) · Cancers · doi:10.3390/cancers13030524 · Cited by 36
Chaudhary, S., Pothuraju, R., Rachagani, S., Siddiqui, J. A., Atri, P., Mallya, K. B., Nasser, M. W., Sayed, Z., Lyden, E. R., Smith, L. M., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.04.004 · Cited by 35
Viganò, L., Locatelli, A., Ulisse, A., Galbardi, B., Dugo, M., Tosi, D., Tacchetti, C., Daniele, T., Győrffy, B., Sica, L., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3185 · Cited by 38
How selective are clinical CDK4/6 inhibitors?
Hendrychová, D., Jorda, R., & Kryštof, V. (2020) · Medicinal Research Reviews · doi:10.1002/med.21769 · Cited by 36
The Intricate Interplay between Cell Cycle Regulators and Autophagy in Cancer
Ziegler, D. V., Huber, K., & Fajas, L. (2021) · Cancers · doi:10.3390/cancers14010153 · Cited by 34
Alvarez-Breckenridge, C. A., Remón, J., Piña, Y., Nieblas‐Bedolla, E., Forsyth, P. A., Hendriks, L. E. L., & Brastianos, P. K. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_352320 · Cited by 32
Li, H., Wu, Y., Zou, H., Koner, S., Plichta, J. K., Tolaney, S. M., Zhang, J., He, Y.-W., Wei, Q., Tang, L., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105186 · Cited by 33
Charge and Size Dual Switchable Nanocage for Novel Triple‐Interlocked Combination Therapy Pattern
Yang, R., Zhang, Z., Fu, S., Hou, T., Mu, W., Liang, S., Gao, T., Guan, L., Fang, Y., Liu, Y., et al. (2020) · Advanced Science · doi:10.1002/advs.202000906 · Cited by 31
Bouchard, G., Garcia-Marques, F. J., Karacosta, L. G., Zhang, W., Bermudez, A., Riley, N. M., Varma, S., Mehl, L. C., Benson, J. A., Shrager, J. B., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1705 · Cited by 32
Tong, J., Tan, X., Song, X., Gao, M., Risnik, D., Hao, S., Ermine, K., Wang, P., Li, H., Huang, Y., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-3062 · Cited by 32
Lee, J. S., Hackbart, H., Cui, X., & Yuan, Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411791 · Cited by 33
Beyond cell cycle regulation: The pleiotropic function of CDK4 in cancer
Ziegler, D. V., Parashar, K., & Fajas, L. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.12.002 · Cited by 32
Cyclin-dependent kinases in cancer: Role, regulation, and therapeutic targeting
Gupta, A., Dagar, G., Chauhan, R., Sadida, H. Q., Al-Marzooqi, S. K., Hashem, S., Shahab Uddin, M. S., Macha, M. A., Akil, A. S. A.-S., Pandita, T. K., et al. (2023) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2023.02.001 · Cited by 30
Song, X., Chen, F., Dai, Y., Sun, Y., Qiu, C., Lin, X., & Xu, R. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02589-8 · Cited by 29
David, S., Ho, G., Day, D., Harris, M., Tan, J., Goel, S., Hanna, G. G., Srivastava, R., Kruss, G., McDowell, L. J., et al. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100939 · Cited by 31
Gadsden, N. J., Fulcher, C. D., Li, D., Shrivastava, N., Thomas, C., Segall, J. E., Prystowsky, M. B., Schlecht, N. F., Gavathiotis, E., & Ow, T. J. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0915 · Cited by 29
Therapeutic potential of CDK4/6 inhibitors in renal cell carcinoma
Sager, R., Backe, S. J., Ahanin, E. F., Smith, G., Nsouli, I. S., Woodford, M. R., Bratslavsky, G., Bourboulia, D., & Mollapour, M. (2022) · Nature Reviews Urology · doi:10.1038/s41585-022-00571-8 · Cited by 29
Palmitoylation prevents B7-H4 lysosomal degradation sustaining tumor immune evasion
Yan, Y., Yu, J., Wang, W., Xu, Y., Tison, K., Xiao, R., Grove, S., Wei, S., Vatan, L., Wicha, M. S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58552-5 · Cited by 33
Novel Therapeutic Strategies for CDK4/6 Inhibitors in Metastatic Castrate-Resistant Prostate Cancer
Kase, A. M., Copland, J. A., & Tan, W. W. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s266085 · Cited by 30
Gianni, L., Colleoni, M. A., Bisagni, G., Mansutti, M., Zamagni, C., Mastro, L. D., Zambelli, S., Bianchini, G., Frassoldati, A., Maffeis, I., et al. (2022) · npj Breast Cancer · doi:10.1038/s41523-021-00377-8 · Cited by 28
Deregulated E2F Activity as a Cancer-Cell Specific Therapeutic Tool
Nakajima, R., Zhao, L., Zhou, Y., Shirasawa, M., Uchida, A., Murakawa, H., Fikriyanti, M., Iwanaga, R., Bradford, A. P., Araki, K., et al. (2023) · Genes · doi:10.3390/genes14020393 · Cited by 32
Zapata, I., Moraes, L. E., Fiala, E. M., Zaldívar‐López, S., Couto, C. G., Rowell, J., & Alvarez, C. E. (2019) · BMC Genomics · doi:10.1186/s12864-019-5531-6 · Cited by 27
Valenzuela, C. A., Quintanilla, R., Olate‐Briones, A., Venturini, W., Mancilla, D., Cayo, Á., Moore‐Carrasco, R., & Brown, N. E. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215292 · Cited by 29
Chen, X., Shu, C., Li, W., Hou, Q., Luo, G., Yang, K., & Wu, X. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00063 · Cited by 27
Griffiths, J. I., Cosgrove, P. A., Medina, E. F., Nath, A., Chen, J., Adler, F. R., Chang, J. T., Khan, Q. J., & Bild, A. H. (2025) · Nature Communications · doi:10.1038/s41467-025-56279-x · Cited by 29
Xie, X., Zheng, W., Chen, T., Lin, W., Liao, Z., Liu, J., & Ding, Y. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s234221 · Cited by 25
Liu, C., Huang, Y., Qin, T., You, L., Lu, F., Hu, D., Xiao, R., Xu, Q., Guo, E., Yang, B., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.12.021 · Cited by 25
Fang, Y., Zhang, Z., Liu, Y., Gao, T., Liang, S., Chu, Q., Guan, L., Mu, W., Fu, S., Yang, H., et al. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c01305 · Cited by 26
Kim, C. G., Kim, M. H., Kim, J. H., Kim, S., Kim, G. M., Kim, T. Y., Ryu, W., Kim, J. Y., Park, H. S., Park, S., et al. (2023) · Breast Cancer Research · doi:10.1186/s13058-022-01601-4 · Cited by 24
Tanaka, Y., Momose, S., Tabayashi, T., Sawada, K., Yamashita, T., Higashi, M., Sagawa, M., Tokuhira, M., Rosenwald, A., Kizaki, M., et al. (2019) · Cancer Science · doi:10.1111/cas.14286 · Cited by 27
Mekonnen, L. B., Tadesse, S., Lenjisa, J. L., Yu, M., Noll, B. D., Heinemann, G. K., Lokman, N. A., Ricciardelli, C., Oehler, M. K., Beck, A. R., et al. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.09.012 · Cited by 25
The Challenges of Treating Patients with Breast Cancer and Obesity
LeVee, A. A., & Mortimer, J. E. (2023) · Cancers · doi:10.3390/cancers15092526 · Cited by 27
Wekking, D., Leoni, V. P., Lambertini, M., Dessì, M., Pretta, A., Cadoni, A., Atzori, L., Scartozzi, M., & Solinas, C. (2023) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2023.10.001 · Cited by 26
Long, B., Yang, X., Xu, X., Li, X., Xu, X., Zhang, X., & Zhang, S. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03205-2 · Cited by 25
Neutrophil-activating secretome characterizes palbociclib-induced senescence of breast cancer cells
Favaretto, G., Rossi, M. N., Cuollo, L., Laffranchi, M., Cervelli, M., Soriani, A., Sozzani, S., Santoni, A., & Antonangeli, F. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03695-5 · Cited by 25
CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells
Digiacomo, G., Fumarola, C., Monica, S. L., Bonelli, M. A., Cavazzoni, A., Galetti, M., Terenziani, R., Eltayeb, K., Volta, F., Zoppi, S., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.942341 · Cited by 24
Jin, D., Tran, N., Thomas, N. J., & Tran, D. D. (2019) · PLoS ONE · doi:10.1371/journal.pone.0223555 · Cited by 27
Palbociclib treatment alters nucleotide biosynthesis and glutamine dependency in A549 cells
Conroy, L. R., Lorkiewicz, P., He, L., Yin, X., Zhang, X., Rai, S. N., & Clem, B. F. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01357-x · Cited by 25
Tai, T.-S., Lin, P., Wu, C., Hung, S., Huang, C., WANG, C.-C., & Su, Y. (2019) · Anticancer Research · doi:10.21873/anticanres.13167 · Cited by 23
Kjoe, P. R. L. M., van der Wall, E., & Schagen, S. B. (2021) · Clinical Breast Cancer · doi:10.1016/j.clbc.2021.08.002 · Cited by 23
Elfgen, C., & Bjelic‐Radisic, V. (2021) · Cancers · doi:10.3390/cancers13235994 · Cited by 23
CDK4/6 blockade provides an alternative approach for treatment of mismatch-repair deficient tumors
Salewski, I., Henne, J., Engster, L., Krone, P., Schneider, B., Redwanz, C., Lemcke, H., Henze, L., Junghanß, C., & Maletzki, C. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2094583 · Cited by 23
Yan, C., Gao, R., Gao, C., Hong, K., Cheng, M., Liu, X., Zhang, Q. H., & Zhang, J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1105117 · Cited by 22
The Evolving Pathways of the Efficacy of and Resistance to CDK4/6 Inhibitors in Breast Cancer
Gomes, I., Abreu, C., Costa, L., & Casimiro, S. (2023) · Cancers · doi:10.3390/cancers15194835 · Cited by 24
Chen, S., Wang, Q., Liao, X., Ge, H., Huo, G., Zhang, L., Chen, N., Zhai, X., Yuan, H., Wang, L., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112239 · Cited by 22
Eoh, K. J., Kim, H. J., Lee, J. W., Kim, L. K., Park, S., Kim, H. S., Kim, Y. T., & Koo, J. P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165813 · Cited by 23
Ono, M., Oba, T., Shibata, T., & Ito, K. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03722-3 · Cited by 23
Wang, X., Shi, W., Wang, X., Lu, J., He, P., Zhang, H., & Chen, X. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01658-w · Cited by 22
Palbociclib enhances activin‐ SMAD ‐induced cytostasis in estrogen receptor‐positive breast cancer
Harada, M., Morikawa, M., Ozawa, T., Kobayashi, M., Tamura, Y., Takahashi, K., Tanabe, M., Tada, K., Seto, Y., Miyazono, K., et al. (2018) · Cancer Science · doi:10.1111/cas.13841 · Cited by 21
Gao, T., Sun, Y., Leng, P., Liu, D., Guo, Q., & Li, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1549520 · Cited by 22
PA28α/β Promote Breast Cancer Cell Invasion and Metastasis via Down-Regulation of CDK15
Li, S., Dai, X., Gong, K., Song, K., Tai, F., & Shi, J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01283 · Cited by 20
Kishino, E., Ogata, R., Saitoh, W., Koike, Y., Ohta, Y., Kanomata, N., & Kurebayashi, J. (2019) · Breast Cancer · doi:10.1007/s12282-019-01035-5 · Cited by 20
Hypophosphorylated pRb knock‐in mice exhibit hallmarks of aging and vitamin C‐preventable diabetes
Jiang, Z., Li, H., Schroer, S. A., Voisin, V., Ju, Y., Pacal, M., Erdmann, N., Shi, W., Chung, P. E. D., Deng, T., et al. (2022) · The EMBO Journal · doi:10.15252/embj.2020106825 · Cited by 18
CDK 4/6 inhibitors for the treatment of meningioma
Young, J. S., Kidwell, R. L., Zheng, A., Haddad, A. F., Aghi, M. K., Raleigh, D. R., Schulte, J. D., & Butowski, N. A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.931371 · Cited by 22
An Overview of CDK Enzyme Inhibitors in Cancer Therapy
Mounika, P., Gurupadayya, B., Kumar, H. Y., & Bannimath, N. (2023) · Current Cancer Drug Targets · doi:10.2174/1568009623666230320144713 · Cited by 23
Chen, P., Chen, S., Chen, Y., Wang, Y., Lin, C.-Y., Chen, C., Tsai, Y., & Hwang, T. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.03.019 · Cited by 20
Aromatase and CDK4/6 Inhibitor-Induced Musculoskeletal Symptoms: A Systematic Review
Andrikopoulou, Α., Fiste, O., Liontos, M., Dimopoulos, M. A., & Zagouri, F. (2021) · Cancers · doi:10.3390/cancers13030465 · Cited by 20
Therapeutic targets in cancer treatment: Cell cycle proteins
Selvaraj, C. (2023) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2023.02.003 · Cited by 19
Cellular senescence: from homeostasis to pathological implications and therapeutic strategies
Li, C., Yuan, Y., Jia, Y., Zhou, Q., Wang, Q., & Jiang, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1534263 · Cited by 21
Advances in immunotherapy and targeted therapy for pancreatic cancer
Zhou, X., Wang, X., Yang, S., & Huang, Z. (2024) · Oncology and Translational Medicine · doi:10.1097/ot9.0000000000000074 · Cited by 19
Kartika, I. D., Kotani, H., Iida, Y., Koyanagi, A., Tanino, R., & Harada, M. (2021) · Cancer Medicine · doi:10.1002/cam4.4410 · Cited by 17
Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2− Early Breast Cancer
Klocker, E. V., Egle, D., Bartsch, R., Rinnerthaler, G., & Gnant, M. (2025) · Drugs · doi:10.1007/s40265-024-02144-y · Cited by 21
Combination of Talazoparib and Palbociclib as a Potent Treatment Strategy in Bladder Cancer
Klein, F. G., Granier, C., Zhao, Y., Pan, Q., Tong, Z., Gschwend, J. E., Holm, P. S., & Nawroth, R. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11050340 · Cited by 19
T Cell-Intrinsic CDK6 Is Dispensable for Anti-Viral and Anti-Tumor Responses In Vivo
Klein, K., Witalisz‐Siepracka, A., Gotthardt, D., Agerer, B., Sternberg, F., Grausenburger, R., Knab, V. M., Bergthaler, A., & Sexl, V. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.650977 · Cited by 19
Anjaneyan, G., Pavithran, K., Duraisamy, P., & Eapen, M. (2022) · BMJ Case Reports · doi:10.1136/bcr-2022-248782 · Cited by 19
Wang, L., Wu, Y., Kang, K., Zhang, X., Luo, R., Tu, Z., Zheng, Y., Guo, L., Wang, H., Tang, M., et al. (2024) · Translational Lung Cancer Research · doi:10.21037/tlcr-24-33 · Cited by 18
Luo, C., Hou, M., Huang, C., Wu, C., Ou‐Yang, F., Li, Q.-L., Wu, C.-C., & Pan, M. (2020) · PubMed Central · Cited by 18
Abemaciclib induces apoptosis in cardiomyocytes by activating the Hippo signaling pathway
Zhou, Y., Li, Y., Shen, J., Li, J., & Li, X. (2020) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmaa066 · Cited by 17
Zhang, Y., He, L., Huang, L., Yao, S., Lin, N., Li, P., Xu, H., Wu, X., Xu, J., Lü, Y., et al. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.503 · Cited by 17
NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition
Llauradó, M., Hijmans, E. M., Gennissen, A. M. C., Wong, N. K. Y., Li, S., Wisman, G. B. A., Hamilton, A., Hoenisch, J., Dawson, A., Lee, C., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0004 · Cited by 16
Gureghian, V., Herbst, H., Kozar, I., Mihajlović, K., Malod‐Dognin, N., Ceddia, G., Angeli, C., Margue, C., Randic, T., Philippidou, D., et al. (2023) · Cancer Gene Therapy · doi:10.1038/s41417-023-00640-z · Cited by 16
Husseiny, E. M., Abulkhair, H. S., El‐Hddad, S. S. A., Osama, N., & El‐Zoghbi, M. S. (2023) · Future Medicinal Chemistry · doi:10.4155/fmc-2023-0139 · Cited by 16
Unbiased discovery of cancer pathways and therapeutics using Pathway Ensemble Tool and Benchmark
Wang, L., Pattnaik, A., Sahoo, S. S., Stone, E., Zhuang, Y., Benton, A., Tajmul, M., Chakravorty, S., Dhawan, D., Nguyen, M. S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51859-9 · Cited by 13
Chen, M., Chen, W., Sun, S., Lu, Y., Wu, G., Xu, H., Yang, H., Li, C., He, W., Xu, M., et al. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.08.034 · Cited by 16
CDK4/RB/E2Fs axis as potential therapeutic target of endometrial cancer
Hu, J., Shen, J., & Sun, J. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.109870 · Cited by 18
Targeting the CDK6 Dependence of Ph+ Acute Lymphoblastic Leukemia
Porazzi, P., Dominici, M. D., Salvino, J. M., & Calabretta, B. (2021) · Genes · doi:10.3390/genes12091355 · Cited by 14
Xu, L., Ding, R., Song, S., Liu, J., Li, J., Ju, X., & Ju, B. (2024) · The Journal of Gene Medicine · doi:10.1002/jgm.3658 · Cited by 16
CDK4/6 Inhibitors Impede Chemoresistance and Inhibit Tumor Growth of Small Cell Lung Cancer
Wen, Y., Sun, X., Zeng, L., Liang, S., Li, D., Chen, X., Zeng, F., Zhang, C., Wang, Q., Zhong, Q., et al. (2024) · Advanced Science · doi:10.1002/advs.202400666 · Cited by 14
Murad, B., Reis, P. C. A., Marinho, A. D., Comini, A. C. M., Xavier, D. P., Pessoa, B., Raheem, F., Ernst, B. J., Mina, L. A., & Batalini, F. (2024) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkae078 · Cited by 15
Translating RB1 predictive value in clinical cancer therapy: Are we there yet?
Indovina, P., Pentimalli, F., Conti, D., & Giordano, A. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.06.003 · Cited by 15
Anti-cancer therapy with cyclin-dependent kinase inhibitors: impact and challenges
Reinius, M., & Smyth, E. C. (2021) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2021.3 · Cited by 14
Chen, P., Tseng, H., Wang, Y., Fang, S., Chen, S., Chen, C., Tsai, S., Chang, Y., Tsai, Y., & Hwang, T. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16080 · Cited by 14
Mavratzas, A., & Marmé, F. (2021) · Breast Care · doi:10.1159/000514561 · Cited by 14
Estrogen Receptor Alpha and ESR1 Mutations in Breast Cancer
Patel, J. M., & Jeselsohn, R. M. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-11836-4_10 · Cited by 15
Inhibition of multiple CDKs potentiates colon cancer chemotherapy via p73-mediated DR5 induction
Tong, J., Tan, X., Hao, S., Ermine, K., Lu, X. Y., Liu, Z., Jha, A., Yu, J., & Zhang, L. (2023) · Oncogene · doi:10.1038/s41388-023-02598-6 · Cited by 13
Adjuvant CDK4/6 Inhibitors for Early Breast Cancer: How to Choose Wisely?
Agostinetto, E., Arecco, L., & de Azambuja, E. (2023) · Oncology and Therapy · doi:10.1007/s40487-023-00250-7 · Cited by 13
Chen, S., Chen, C., Lin, H.-C., Yeh, S., Hwang, T., & Chen, P. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.07.026 · Cited by 13
Chang, M., Huhn, S. C., Nelson, L., Betenbaugh, M. J., & Du, Z. (2022) · Biotechnology and Bioengineering · doi:10.1002/bit.28050 · Cited by 13
Unexpected toxicity of CDK4 /6 inhibitor palbociclib and radiotherapy
van Aken, E. S. M., Beeker, A., Houtenbos, I., Pos, F. J., Linn, S. C., Elkhuizen, P. H. M., & de Jong, M. C. (2021) · Cancer Reports · doi:10.1002/cnr2.1470 · Cited by 13
Growth Inhibitory Efficacy of Chinese Herbs in a Cellular Model for Triple-Negative Breast Cancer
TELANG, N. T., Nair, H. B. B., & Wong, G. Y. (2021) · Pharmaceuticals · doi:10.3390/ph14121318 · Cited by 12
Rational design of poly-L-glutamic acid-palbociclib conjugates for pediatric glioma treatment
Melnyk, T., Masiá, E., Zagorodko, O., Conejos‐Sánchez, I., & Vicent, M. J. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.01.079 · Cited by 12
Metadata
- Authors
- Klein, M. E., Kovatcheva, M., Davis, L. E., Tap, W. D., & Koff, A.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Oregon Health & Science University (US)
- Corresponding author
- Koff, Andrew
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2018-07
- Volume
- 34
- Issue
- 1
- Pages
- 9-20
- ISSN
- 1535-6108 (ISSN-L)
- PMC
- PMC6039233
- OpenAlex
- W2799372852
- Cited by
- 378
- References
- 70
- Citations by year
- 2026: 22 · 2025: 50 · 2024: 63 · 2023: 46 · 2022: 37 · 2021: 58 · 2020: 55 · 2019: 31 · 2018: 16
- FWCI
- 7.35
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cancer Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (P30 CA008748, CA140146)
- Sarcoma Foundation of America
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- CDK4/6 inhibitors, cyclin-dependent kinases, mechanism of action, breast cancer, letrozole, combination therapy, anticancer activity, dosing regimen
- MeSH terms
- Animals, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Humans, Neoplasms, Drug Design, Signal Transduction, Cellular Senescence, Protein Kinase Inhibitors, Cell Proliferation, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Molecular Targeted Therapy, Cell Cycle Checkpoints
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
